Dxcover, a UK-based company advancing early cancer detection through AI-powered multiomic technology, has officially launched its United States headquarters in Nashville, Tennessee. This expansion marks a strategic step to commercialise its PANAROMIC cancer test within the largest global life sciences market.
Dxcover’s Drop. Dry. Detect. method provides a cost-effective, high-throughput, non-invasive cancer screening platform using infrared spectroscopy combined with AI-driven spectral analysis. The new U.S. facilities will support partnerships with local biotech and healthcare organizations, facilitate manufacturing of its spectroscopy platform, and serve as an R&D hub to further drive innovation in cancer diagnostics.
CEO and Co-founder Matthew J. Baker, Ph.D., highlighted Nashville’s vibrant healthcare ecosystem as an ideal environment for collaboration with research institutes and biotech startups, underscoring the company’s commitment to expanding access to precision medicine and early cancer detection solutions. Dxcover’s PANAROMIC technology captures comprehensive biological signatures from small blood samples, enabling earlier diagnosis and improved patient outcomes across various cancers such as brain, colorectal, lung, and pancreatic.
The scalable platform aims to enhance healthcare equity by reaching underserved populations globally. Baker noted ongoing efforts to validate the technology, including a large-scale brain cancer diagnostic study involving 2,200 patients at seven European sites.
Follow MEDWIRE.AI for the latest in cancer diagnostics and AI innovation in MedTech.
